Professional Documents
Culture Documents
Portofolio en-ES Life Sciences
Portofolio en-ES Life Sciences
Translation - Spanish
A. Informacin del estudio de
investigacin
Lo invitamos a participar en este
subestudio quirrgico, puesto que ya
participa en el estudio principal de la
investigacin clnica (CSL627_1001) y
tiene una intervencin quirrgica
programada. Para que pueda decidir si
acepta participar en el subestudio o no,
primero debe conocer bien cules son los
posibles riesgos y beneficios de tomar
una decisin informada. Este proceso se
conoce como consentimiento informado.
Un comit de tica dio su autorizacin
para este estudio. Este comit est
integrado por un grupo de expertos que
velan por la proteccin de los derechos,
la seguridad y el bienestar de los
pacientes que participan en un estudio.
Este formulario contiene informacin
detallada del subestudio quirrgico al
cual se le invita a participar. Es de suma
importancia que lea y asimile la siguiente
informacin. No dude en consultar al
mdico del estudio o al personal de la
investigacin para que lo ayuden a
entender en qu consiste el subestudio y
lo que se espera de usted.
Translation - Spanish
Introduccin y propsito del estudio
En la actualidad, usted participa en un
estudio clnico para evaluar la capacidad
(eficacia) del medicamento 627 para
tratar y controlar el sangrado de los
pacientes con hemofilia, as como de
garantizar la seguridad de su uso.
El propsito del subestudio quirrgico es
analizar la eficacia del Frmaco 627
durante los procedimientos quirrgicos,
as como la seguridad de dicho
surgery.
Study Treatment and Procedures
Your study doctor will adjust your dose
regimen based on the type of surgery,
your health condition, and your
pharmacokinetic (PK) data.
Prior to surgery you will be dosed with
DRUG 627 in a manner similar to the
preparation of any subject with
hemophilia A with any factor VIII
product before surgery. You will
temporarily suspend participation in the
main part of the study while undergoing
preparation for surgery and also for
some time afterwards, usually between
10 to 14 days.
Immediately before surgery you may be
treated by bolus (single injection) or
continuous infusion.
By bolus: At least 48 hours prior to
surgery, you will suspend participation
in the main study. Just prior to surgery, a
bolus dose of DRUG 627 will be
administered. Treatment with DRUG
627 will be continued for a minimum of
10 days and then tapered off between 10
to 14 days based on your doctors
judgment. After 14 days, if there are no
complications or surgical considerations,
you may resume participation in the
main study.
By continuous infusion: At least 48
hours prior to surgery, you will suspend
participation in the main study. A bolus
dose of DRUG 627 will be administered
immediately prior to surgery. Following
the bolus dose, continuous infusion will
be started. The dose of the continuous
infusion will be adjusted as required
during and after surgery. Between 10
to14 days after surgery, if there are no
complications or other surgical
considerations, the continuous infusion
will be discontinued and you may
resume participation in the main study.
English to Spanish: CLINICAL TRIAl AGREEMENT Detailed field: Medical Pharmaceutical- legal
The parties desire to conduct a clinical
trial (the Study) to gather information
regarding the performance of CSL627;
Recombinant Factor VIII (rFVIII) and
Recombinant Human Antihaemophiliac